dc.creator | McIntyre, N. A. | en |
dc.creator | McInnes, C. | en |
dc.creator | Griffiths, G. | en |
dc.creator | Barnett, A. L. | en |
dc.creator | Kontopidis, G. | en |
dc.creator | Slawin, A. M. Z. | en |
dc.creator | Jackson, W. | en |
dc.creator | Thomas, M. | en |
dc.creator | Zheleva, D. I. | en |
dc.creator | Wang, S. | en |
dc.creator | Blake, D. G. | en |
dc.creator | Westwood, N. J. | en |
dc.creator | Fischer, P. M. | en |
dc.date.accessioned | 2015-11-23T10:39:15Z | |
dc.date.available | 2015-11-23T10:39:15Z | |
dc.date.issued | 2010 | |
dc.identifier | 10.1021/jm901660c | |
dc.identifier.issn | 222623 | |
dc.identifier.uri | http://hdl.handle.net/11615/30856 | |
dc.description.abstract | Following the recent discovery and development of 2-anilino-4-(thiazol-5- yl)pyrimidine cyclin dependent kinase (CDK) inhibitors, a program was initiated to evaluate related ring-constrained analogues, specifically, 2-methyl- and 2-amino-N-aryl-4,5-dihydrothiazolo[4,5-/!]quinazolin-8-amines for inhibition of CDKs. Here we report the rational design, synthesis, structure-activity relationships (SARs), and cellular mode-of-action profile of these second generation CDK inhibitors. Many of the analogues from this chemical series inhibit CDKs with very low nanomolar Ki values. The most potent compound reported in this study inhibits CDK2 with an IC50 of 0.7 nM ([ATP] = 100μM). Furthermore, an X-ray crystal structure of 2-methyl-N-(3-(nitro) phenyl)-4,5-dihydrothiazolo[4,5-h]quinazolin-8-amine (11g), a representative from the chemical series in complex with cyclin A-CDK2, is reported, confirming the design rationale and expected binding mode within the CDK2 ATP binding pocket. © 2010 American Chemical Society. | en |
dc.source.uri | http://www.scopus.com/inward/record.url?eid=2-s2.0-77949346933&partnerID=40&md5=b9a7cf416ccedb62eb86f1be2f43bbec | |
dc.subject | 2 methyl n [3 (nitro)phenyl] 4,5 dihydrothiazolo[4,5 h]quinazolin 8 amine | en |
dc.subject | 2 methyl n phenyl 4,5 dihydrothiazolo[4,5 h]quinazolin 8 amine | en |
dc.subject | 2 methyl n phenylthiazolo 4,5 dihydrothiazolo[4,5 h]quinazolin 8 amine | en |
dc.subject | cyclin dependent kinase | en |
dc.subject | n,2 dimethyl n (3 nitrophenyl) 4,5 dihydrothiazolo[4,5 h]quinazolin 8 amine | en |
dc.subject | pyrimidine derivative | en |
dc.subject | unclassified drug | en |
dc.subject | article | en |
dc.subject | crystal structure | en |
dc.subject | drug design | en |
dc.subject | drug screening | en |
dc.subject | drug synthesis | en |
dc.subject | enzyme inhibition | en |
dc.subject | IC 50 | en |
dc.subject | structure activity relation | en |
dc.subject | X ray | en |
dc.subject | Aminoquinolines | en |
dc.subject | Antineoplastic Agents | en |
dc.subject | Blotting, Western | en |
dc.subject | Cell Line, Tumor | en |
dc.subject | Cell Proliferation | en |
dc.subject | Crystallography, X-Ray | en |
dc.subject | Cyclin-Dependent Kinases | en |
dc.subject | Humans | en |
dc.subject | Inhibitory Concentration 50 | en |
dc.subject | Magnetic Resonance Spectroscopy | en |
dc.subject | Models, Molecular | en |
dc.subject | Protein Kinase Inhibitors | en |
dc.subject | Structure-Activity Relationship | en |
dc.subject | Thiazoles | en |
dc.title | Design, synthesis, and evaluation of 2-methyl- and 2-amino-N-aryl-4,5- dihydrothiazolo[4,5-h]quinazolin-8-amines as ring-constrained 2-anilino-4-(thiazol-5-yl)pyrimidine cyclin-dependent kinase inhibitors | en |
dc.type | journalArticle | en |